Müller-Oerlinghausen B, Passoth P M, Poser W, Pudel V
Int Pharmacopsychiatry. 1979;14(6):350-62. doi: 10.1159/000468400.
The oral glucose tolerance test (oGTT) was performed twice in patients under long-term lithium treatment. Blood glucose and plasma insulin were determined. The oGTT results were evaluated by three criteria (Köbberling-Creutzfeldt, WHO, and Epidemiological Study Group of the European Diabetes Association) and were compared to two representative reference studies from normal populations. The frequency of impaired glucose tolerance in the patients was three times higher than expected on the basis of the studies on normal populations. The variability of the oGTT curves between the first and second tests as well as the steepness of the time-course of the 'insulinogenic index' suggested mild disturbances of carbohydrate metabolism (mild diabetes) in some of the patients. It is considered unlikely that the impairment of glucose tolerance in the patients was a direct pharmacological effect of lithium salts. The possible role of age, sex, manic-depressive disease, additional medication, and particularly obesity in the effects of long-term lithium treatment on glucose tolerance is discussed. The authors suggest that the oGTT should be carried out periodically in long-term, lithium-treated patients over the age of 40 years in order to detect abnormalities in their carbohydrate metabolism.
对长期接受锂盐治疗的患者进行了两次口服葡萄糖耐量试验(oGTT)。测定了血糖和血浆胰岛素水平。oGTT结果依据三项标准(克伯林 - 克罗伊茨费尔特标准、世界卫生组织标准以及欧洲糖尿病协会流行病学研究组标准)进行评估,并与两项来自正常人群的代表性参考研究进行比较。患者中糖耐量受损的频率比基于正常人群研究预期的高出三倍。第一次和第二次试验之间oGTT曲线的变异性以及“胰岛素生成指数”时间进程的陡峭程度表明部分患者存在轻度碳水化合物代谢紊乱(轻度糖尿病)。患者糖耐量受损不太可能是锂盐的直接药理作用。文中讨论了年龄、性别、躁狂抑郁症、其他药物治疗,尤其是肥胖在长期锂盐治疗对糖耐量影响方面可能发挥的作用。作者建议,对于40岁以上长期接受锂盐治疗的患者,应定期进行oGTT,以检测其碳水化合物代谢异常情况。